Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.

woman in a laboratory microscope with microscope slide in hand.toned image.

Allergan PLC tried to put the most positive spin on it, but top-line two-year data from a Phase IIb study of its lead NASH candidate cenicriviroc has analysts wondering what’s the drug’s benefit will be if any. With Allergan revealing Sept. 22 that after two years of treatment, cenicriviroc (CVC) showed no meaningful difference compared to placebo in reducing fibrosis score in NASH patients, Credit Suisse went as far as removing potential revenue for the drug from its modeling.

The Dublin-domiciled specialty pharma claimed that the two-year data from CENTAUR testing CVC, a dual CCR2/CCR5 inhibitor, “supports continued development”...

Welcome to Scrip

Create an account to read this article

More from Clinical Trials

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from R&D

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.